Cell therapy for advanced ovarian, stomach, or sarcoma cancers
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests an experimental cell therapy called MDG1015 for certain advanced cancers that have stopped responding to standard treatments. The therapy uses your own immune cells, which are modified in the lab to find and attack cancer cells that carry the NY-ESO-1 or LAGE-1a protein.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and weigh at least 88 pounds (about 40 kg).
- You must have one of these cancers: high-grade serous or endometrioid ovarian cancer, primary peritoneal or fallopian tube cancer, stomach or esophageal (junction) adenocarcinoma, myxoid (round cell) liposarcoma, or synovial sarcoma.
- A blood test must show you have the HLA-A*02:01 tissue type (a genetic marker).
- Your tumor must have a specific protein marker called NY-ESO-1 or LAGE-1a.
- You must have already tried standard treatments that help with your type of cancer, but they are no longer effective.
- You need to be in generally good health (able to care for yourself, walk, etc.) and have enough organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new kind of immune therapy using your own natural killer (NK) cells that are specially trained to find and attack cancer cells that have the NY-ESO-1 target. It is for people with certain sarcomas or other advanced solid tumors that have not responded to prior treatments.
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to target and fight ovarian cancer that has returned or stopped responding to standard treatments. The therapy uses cells from your own body that have been modified in the lab to recognize and attack cancer cells.
This trial tests an engineered immune cell treatment (NY-ESO-1 TCR-T) for people with advanced soft tissue sarcoma that has returned or spread after standard treatment. It aims to treat cancer cells that show a specific marker (NY-ESO-1) in the tumor.
This study tests an experimental therapy called SCT-001 CAR T cells, made from your own immune cells, for ovarian cancer that has not responded to standard treatments. The goal is to see if these engineered cells can find and attack your cancer cells, which could help shrink or control the disease.
This study tests an immunotherapy treatment for people with advanced solid tumors, including ovarian cancer, sarcoma, prostate, breast, lung, and others. It is designed for tumors that show a specific marker called NY-ESO-1, and aims to see if the treatment can help shrink or control the cancer.
This study tests a customized immune-cell treatment made from your own T cells to attack cancers that have NY-ESO-1. It may help shrink tumors in people with metastatic or hard-to-treat cancer when other treatments have not worked.
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.